Racial disparities in immune-related adverse events of immune checkpoint inhibitors and association with survival based on clinical and biochemical responses

Table 1 Patient characteristics

			irAE
	Overall		Yes		No
	n	%	n	%	n	%
Gender							0.8120
Female	129	44.0	41	45.1	88	43.6
Male	164	56.0	50	54.9	114	56.4
Race							0.0141
White	140	47.8	55	60.4	85	42.1
Black	122	41.6	28	30.8	94	46.5
Asian	13	4.4	4	4.4	9	4.5
Hispanic	2	0.7	0	0	2	1.0
Native American	1	0.3	1	1.1	0	0
Other	11	3.8	1	1.1	10	5.0
Unknown	4	1.4	2	2.2	2	1.0
Death							0.1488
No	131	44.7	35	38.5	96	47.5
Yes	162	55.3	56	61.5	106	52.5
PDL1 positive							0.0695
Yes	71	24.2	25	27.5	46	22.8
No	70	23.9	15	16.5	55	27.2
Missing	152	51.9	51	56.0	101	50.0
PDL1 expression							0.0354
< 50%	69	23.5	16	17.6	53	26.2
≥ 50%	32	10.9	14	15.4	18	8.9
Missing	192	65.5	61	67.0	131	64.9
Line of therapy							0.9432
1	85	29.0	29	31.9	56	27.7
2	130	44.4	37	40.7	93	46.0
3	35	11.9	12	13.2	23	11.4
4	17	5.8	5	5.5	12	5.9
5	8	2.7	2	2.2	6	3.0
6	2	0.7	1	1.1	1	0.5
7	2	0.7	0	0	2	1.0
8	1	0.3	0	0	1	0.5
Missing	13	4.4	5	5.5	8	4.0
Progression							0.0140
Yes	121	41.3	28	30.8	93	46.0
No	172	58.7	63	69.2	109	54.0

irAE: Immune-related adverse events; PDL1: Programmed death ligand 1.